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Abstract
Background: Treatment of mild-moderate Alzheimer’s disease (AD) subjects (N = 119) for 52 weeks with the SIRT1
activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities
of daily living (ADL) scores.
Methods: For this retrospective study, we examined banked CSF and plasma samples from a subset of AD subjects
with CSF Aβ42 <600 ng/ml (biomarker-confirmed AD) at baseline (N = 19 resveratrol-treated and N = 19 placebo-treated).
We utilized multiplex Xmap technology to measure markers of neurodegenerative disease and metalloproteinases
(MMPs) in parallel in CSF and plasma samples.
Results: Compared to the placebo-treated group, at 52 weeks, resveratrol markedly reduced CSF MMP9 and increased
macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2. Compared to baseline,
resveratrol increased plasma MMP10 and decreased IL-12P40, IL12P70, and RANTES. In this subset analysis, resveratrol
treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and
CSF Aβ42 levels during the 52-week trial, but did not alter tau levels.
Conclusions: Collectively, these data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and
induces adaptive immunity. SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative
disorders.
Trial registration: ClinicalTrials.gov NCT01504854
Keywords: Resveratrol, Matrix metalloproteinase-(MMP)-9, Alzheimer, Interleukin-4, Macrophage-derived chemokine
(MDC)
Background
Increasing age is the primary risk factor for Alzheimer’s
disease (AD), even in individuals with high genetic risk.
The mild stressor caloric restriction (CR)—or consum-
ing ~2/3 normal daily calories—postpones and pre-
vents diseases of aging in animal models and perhaps
also in man. In contrast, diabetes mellitus and caloric
excess (obesity, particularly during midlife) accelerate the
onset of AD, suggesting a link between glucose/energy
metabolism and amyloid precursor protein/β-amyloid
(Aβ) metabolism. While the mechanism of CR benefits
remains unclear, activation of sirtuins, notably SIRT1, may
be a critical molecular pathway. SIRT1 deacetylase activity
is regulated by NAD+/NADH—coupling cellular energy
balance to epigenetic transcriptional regulation. Resvera-
trol, a potent SIRT1 activator and pharmacologic mimic
of CR, is a polyphenol found naturally in red grapes,
peanuts, and many other plant species. Similar to CR, treat-
ment of transgenic mouse models of AD with resveratrol
decreases behavioral deficits and central nervous system
(CNS) Aβ deposition with aging [1].
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We hypothesized that molecular mechanisms of aging,
specifically SIRT1, may be exploited as a target for de-
velopment of AD therapeutics. Given the proven safety
of resveratrol and promising preclinical data, we enrolled
119 subjects in a phase 2 randomized, double-blind,
placebo-controlled trial of resveratrol in subjects with
mild-moderate AD (with dosage stepped up to 2 g pure,
synthetic resveratrol by mouth daily, for 12 months) [2].
High-dose oral resveratrol treatment is safe and well-
tolerated—the only significant adverse effect is weight
loss. Low nanomolar native resveratrol is detectable in
cerebrospinal fluid (CSF), suggesting CNS penetration
and a high-affinity molecular target (or targets). Compared
to placebo, resveratrol stabilizes the progressive decline in
CSF Aβ40 and plasma Aβ40 levels as dementia advances.
In individuals with biomarker-confirmed AD (CSF
Aβ42 <600 ng/ml) at baseline, resveratrol also stabilizes
CSF Aβ42 levels [2]. Despite the phase 2 trial being under-
powered to detect clinical benefits, resveratrol attenuated
decline in the Alzheimer’s Disease Cooperative Study-
Activity of Daily Living (ADCS-ADL) score during the 12-
month study. Aging is also a major risk factor for cancer,
and fewer cancers were found in the resveratrol-treated
group (one versus seven cancers in six participants in the
placebo group). Collectively, these data support the notion
that targeting molecular mechanisms of aging may point
to therapeutic strategies that postpone or prevent diseases
of aging—in parallel. With proven safety and suggestions
of efficacy in the phase 2 trial, the putative benefits of res-
veratrol and other sirtuin activator compounds (STACs)
should be further examined in clinical studies.
Paradoxically, resveratrol treatment increased brain
volume loss in AD subjects, compared to the placebo-
treated group. Since CSF tau and phospho-tau levels
are unaffected (suggesting no treatment effect on neuronal
loss), we hypothesize that resveratrol has potent anti-
inflammatory effects in AD brain—with decreased CNS
edema as the etiology of greater brain volume loss. Similar
effects are found with anti-amyloid immunotherapies for
AD [3] and effective drugs for multiple sclerosis (MS) are
also known to be associated with “pseudoatrophy” [4]. To
test the putative anti-inflammatory effects of resveratrol in
AD brain, we measured pro- and anti-inflammatory cyto-
kines and chemokines, and metalloproteinases, in banked
samples of CSF and plasma from a subset of individuals
with biomarker-confirmed AD (CSF Aβ42 <600 ng/ml) in
the phase 2 trial. Consistent with our hypothesis, we
found significant anti-inflammatory effects of resveratrol in
the CSF of treated AD subjects. Our data also suggest that
resveratrol treatment preserved the integrity of the blood-
brain barrier (BBB) in AD. Collectively, these exploratory
findings lend support to the notion that targeting molecular
pathways of aging may lead to novel therapies to postpone
or prevent diseases of aging, including AD.
Methods
Patient demographics
With the Alzheimer’s Disease Cooperative Study, we
recently completed a randomized, placebo-controlled,
double-blind, multi-site, phase 2 trial of resveratrol in
individuals with mild to moderate dementia due to
AD [2]. The study drug was pure, synthetic resveratrol
powder (encapsulated) versus matching placebo. Con-
comitant use of FDA-approved medications for AD
(e.g., cholinesterase inhibitors) was allowed. The two
randomized groups were similar at baseline with the
exception that duration of diagnosis was longer in the
placebo group. Participants (total N = 119) were ran-
domized to placebo or resveratrol 500 mg orally once
daily (with a dose escalation by 500-mg increments
every 13 weeks, ending with 1000 mg twice daily). The
total treatment duration was 52 weeks. Dropout was
less than anticipated, with N = 56 completing week 52
in the resveratrol arm and N = 48 completing week 52
in the placebo arm. Outcomes included safety and tolerabil-
ity as well as effects on AD biomarkers (plasma Aβ40 and
Aβ42, CSF Aβ40, Aβ42, tau, and phospho-tau181) and
volumetric MRI (primary outcomes). Clinical outcomes
(secondary) were also examined. Detailed pharmacokinetics
were obtained in a subset (n = 15) at baseline and at weeks
13, 26, 39, and 52. As expected, oral resveratrol was rapidly
metabolized with limited bioavailability. However, resvera-
trol and its major metabolites were measurable in plasma
and CSF—demonstrating penetration of the blood-brain
barrier. The only significant adverse event was weight loss.
Compared to a decline found in the placebo group, plasma
Aβ40 and CSF Aβ40 levels were stabilized by resveratrol. In
the subset of individuals with biomarker-confirmed AD
(baseline Aβ42 <600 ng/ml), resveratrol treatment also
stabilized CSF Aβ42. Brain volume loss was increased
by resveratrol treatment (3 versus 1%), suggesting a
potent anti-inflammatory effect. The activities of daily
living scale demonstrated less decline with resveratrol
treatment, but the phase 2 study was inadequately powered
to determine clinical outcomes. High-dose oral resver-
atrol is safe and well-tolerated in older individuals
with AD. Further studies are needed to interpret the
clinical and biomarker changes associated with resver-
atrol treatment.
Human Neurodegenerative Disease Magnetic Bead Panels
We used a multiplex Xmap technology that uses magnetic
microspheres internally coded with two fluorescent dyes
to measure markers of neurodegeneration (Millipore,
Cat#: HNABTMAG-68K). All samples including placebo
and resveratrol at baseline and 52 weeks were analyzed in
parallel using the same reagents. Through precise combi-
nations of these two dyes, multiple proteins are measured
within the sample. Each of these spheres is coated with a
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specific capture antibody. The capture antibody binds to
the detection antibody and a reporter molecule, complet-
ing the reaction on the surface of the bead. CSF or plasma
(25 μl) was incubated overnight at 4 °C with 25 μl of a
mixed bead solution, containing human total tau, p-
tau181, Aβ42, and Aβ40 (CSF Aβ40 is diluted 1:10).
After washing, samples were incubated with 25 μl detec-
tion antibody solution for 1.5 h at room temperature.
Streptavidin-phycoerythrin (25 μl) was added to each well
containing the 25 μl of detection antibody solution. Sam-
ples were then washed and suspended in 100 μl of sheath
fluid. Samples were then run on MAGPIX with Xponent
software. The median fluorescent intensity (MFI) data was
analyzed using a 5-parameter logistic or spline curve-
fitting method for calculating analyte concentrations in
samples. We also performed multiplex ELISA (Millipore,
CAT#: HCYTOMAG-60K) to profile a panel of plasma
and CSF markers that are indicative of inflammation,
including human EGF, FGF-2, Eotaxin, TGF-α, G-CSF,
Flt-3L, GM-CSF, Fractalkine, IFNα2, IFNγ, GRO, IL-10,
MCP-3, IL-12P40, MDC, IL-12P70, PDGF-AA, IL-13,
PDGF-AB/BB, IL-15, sCD40L, IL-17A, IL-1RA, IL-1α, IL-
9, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10,
MCP-1, MIP-1α, MIP-1β, RANTES, TNFα, TNFβ, and
VEGF.
Matrix metalloprotease ELISA
Xmap technology uses magnetic microspheres that are
internally coded with two fluorescent dyes. Through pre-
cise combinations of these two dyes, multiple proteins
are simultaneously measured within a sample. Each of
these spheres is coated with a specific capture antibody.
The capture antibody binds to the detection antibody
and a reporter molecule, completing the reaction on the
surface of the bead. All samples including placebo and
resveratrol at baseline and 52 weeks were analyzed in
parallel using the same reagents. A total of 25 μl human
CSF or plasma was incubated overnight at 4 °C with
25 μl of a mixed bead solution, containing human matrix
metalloproteinase (MMP)-3, MMP-12, and MMP-13
(Millipore Cat# HMMP1MAG-55K) or human MMP-1,
MMP-2, MMP-7, MMP-9, and MMP-10 (Millipore Cat#
HMMP2MAG-55K). Following extensive washing of the
plate, samples were incubated with 25 μl of detection
antibody solution for 1.5 h at room temperature and
25 μl of streptavidin-phycoerythrin was added to each
well. Samples were then washed and suspended in 100 μl
of sheath fluid. Samples were then run on MAGPIX
with Xponent software. The median fluorescent inten-
sity (MFI) data was analyzed using a five-parameter
logistic or spline curve-fitting method for calculating
analyte concentrations in samples according to manu-
facturer’s protocols.
Statistical analysis
The inflammatory outcomes measured here are all ex-
ploratory, post hoc analyses. Data are summarized as
raw values, range as appropriate, and mean ± SD for N= 19
in the placebo group and N= 19 in the resveratrol group,
unless otherwise indicated. All graphs and statistical ana-
lyses were performed in Graph Pad Prism Software version
5.01 (Graph Pad Prism Software, Inc. CA. USA). For base-
line comparison between the two treatment arms, unpaired
t tests assuming both equal and unequal variances and
Wilcoxon rank sum tests were performed to compare bio-
markers and clinical variables. For categorical variables,
Pearson’s χ2 tests were used for comparison. Paired t tests
were performed within groups at baseline versus 52 weeks
of treatment, and unpaired t tests were performed for com-
parison of placebo and resveratrol treatment. We also fitted
simple linear regression to see the associations between
cognitive score (MMSE) and each biomarker among all of
these individuals. The Benjamini and Hochberg (BH) mul-
tiple test correction is applied to control the false discovery
rate at 0.05. p values (*indicates statistical significance after
BH adjustment) are summarized in Tables 1 and 2.
Standard protocol approvals, registrations, and patient
consents
This study was conducted in accordance with Good Clin-
ical Practice guidelines. Informed consent was obtained
from participants and study partners. The study was con-
ducted under local institutional review board supervision,
under Food and Drug Administration IND 104205, and
registered at ClinicalTrials.gov (NCT01504854).
Results
CSF biomarkers
At baseline, the levels of CSF biomarkers between the
placebo group and resveratrol group were not signifi-
cantly different (Table 1). The level of CSF MMP9 was
significantly reduced in the placebo group between base-
line and 52 weeks (Fig. 1a), and MMP9 was further re-
duced (48%) at 52 weeks in the resveratrol group. No
change in MMP9 was detected in the plasma (Table 2).
Additionally, the level of interleukin (IL)-4 did not
change in the placebo group, but CSF IL-4 was increased
(Fig. 1b) in the resveratrol group. The CSF levels of
macrophage-derived chemokine (MDC) (Fig. 1c) and
fibroblast growth factor (FGF)-2 (Fig. 1d) were also in-
creased after 52 weeks of resveratrol treatment com-
pared to baseline, with no changes in these molecules in
plasma (Table 1). There was no change in total CSF tau
or hyper-phosphorylated (p-tau)181 levels in the resvera-
trol group and other inflammatory markers (Table 1) did
not change. The level of CSF Aβ42 was significantly re-
duced in the placebo (Fig. 1e) and resveratrol group at
52 weeks compared to baseline, consistent with our
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previous data [2]. However, the decline of CSF Aβ42 in
the placebo group was greater than the decline in the
resveratrol group (p = 0.0618). Furthermore, CSF Aβ40
was significantly reduced in the resveratrol group at
52 weeks compared to baseline (Fig. 1f ). Multiple test
corrections to control for a false discovery rate <0.05
were performed and the significant associations in CSF
markers were unchanged after this analysis.
Plasma biomarkers
At baseline plasma level of each biomarker between the
placebo group and resveratrol group were not signifi-
cantly different (Table 2). The plasma level of MMP10
was increased at 52 weeks of resveratrol treatment com-
pared to baseline and placebo (Fig. 2a), and MMP10 did
not change in CSF (Table 1). MMP3 and MMP2 did not
change in the CSF (Table 1) or plasma and MMP1,
MMP12, and MMP13 did not change in plasma
(Table 2). Plasma IL-1R4 (Fig. 2b) and IL-12P40 (Fig. 2c)
were increased at 52 weeks compared to baseline in the
placebo group, but this increase was slightly reduced in
the resveratrol group. The plasma levels of IL-12P70
(Fig. 2d) did not change with placebo but was reduced at
52 weeks compared to baseline in the resveratrol group
before multiple test adjustment. Plasma tumor necrosis
factor (TNF)-α (Fig. 2e) was increased at 52 weeks com-
pared to baseline with placebo and did not change in the
resveratrol group. Plasma levels of RANTES/CCL5
(Fig. 2f ) did not change with placebo but was reduced at
52 weeks compared to baseline in the resveratrol group.
The plasma level of IL-8 (Table 2) was reduced at 52 weeks
in the resveratrol group compared to placebo. No changes
were observed in other markers (Tables 1 and 2) between
groups. However, statistical associations in plasma markers
Table 1 Summary of statistical tests of null changes between baseline and 52 weeks and tests of null differences at baseline using
all detected molecules in CSF of patients treated with placebo (N = 19) or resveratrol (N = 19)
Analytes Between baseline and 52 weeks At baseline





Placebo Active Placebo Active Unpaired t test (unequal) Unpaired t test (equal) Wilcoxon signed rank test
Aβ40 0.0031** 0.0014** 0.0784 0.0066** 0.0029** 0.3579 0.3587 0.5284
Aβ42 0.0112* 0.0027** 0.0784 0.0105* 0.0034** 0.3764 0.3739 0.4986
pTau 181 0.0665 0.6498 0.4409 0.0649 0.2891 0.7043 0.7044 0.9319
tTau 0.91 0.3673 0.4614 0.9622 0.2163 0.5769 0.5638 0.9373
MMP-9 0.0474* 0.0027** 0.0241* 0.0771 0.0034** 0.8751 0.8737 1.0000
MMP-3 0.6098 0.5437 0.942 0.5016 0.6848 0.6911 0.6882 0.9311
MMP-2 0.5781 0.2322 0.9759 0.7049 0.3388 0.8828 0.8828 0.8509
MMP-10 0.4965 0.3175 0.9999 0.9341 0.5935 0.9415 0.9410 0.6807
FGF-2 0.3676 0.0248* 0.269 0.2128 0.0273* 0.6751 0.6774 0.5508
TGFα 0.8693 0.0829 0.4257 0.61 0.2324 0.5571 0.5519 0.9843
G-CSF 0.0532 0.1196 0.6722 0.0942 0.1563 0.2042 0.2422 0.4195
MCP-3 0.4751 0.0802 0.2922 0.5625 0.1094 0.2366 0.2305 0.2948
MDC 0.8121 0.001*** 0.0505 0.8938 0.0009*** 0.0458 0.0566 0.0678
PDGF-AA 0.9866 0.1106 0.0728 0.804 0.0787 0.9883 0.9886 0.8957
IL-4 0.9647 0.0085** 0.1828 0.6875 0.0167* 0.0860 0.0992 0.0748
PDGF-AB/BB 0.1752 0.4337 0.3356 0.0463* 0.057 0.6349 0.6261 0.7881
IL-8 0.262 0.1177 0.1594 0.57 0.0465* 0.9648 0.9648 0.6450
Flt-3L 0.9602 0.1132 0.5639 0.8498 0.155 0.8880 0.8880 0.8109
Fractalkine 0.791 0.4409 0.5973 0.6701 0.9382 0.4541 0.4543 0.8641
IFNα2 0.8832 0.4182 0.2943 0.8361 0.7547 0.8727 0.8729 0.6194
IL-15 0.9469 0.3587 0.3867 0.816 0.4263 0.7049 0.7029 0.6813
IL-7 0.8148 0.4458 0.3147 0.8384 1 0.4650 0.4553 0.4305
IP-10 0.2769 0.4091 0.405 0.6026 0.7368 0.3900 0.3918 0.8509
MCP-1 0.8089 0.5809 0.7419 0.421 0.8971 0.8650 0.8650 0.9864
MIP-1b 0.3973 0.2909 0.6174 0.3621 0.2188 0.7722 0.7632 0.8401




Moussa et al. Journal of Neuroinflammation  (2017) 14:1 Page 4 of 10
did not hold after multiple test correction, suggesting that
samples from a larger number of subjects may be required
to discover putative significant effects.
Cognitive outcomes
A reduction in mini-mental score examination (MMSE)
scores was observed at 52 weeks compared to baseline
in the placebo group (Fig. 3a, p < 0.01), but no significant
change was detected in MMSE between baseline and
52 weeks with resveratrol treatment. ADCS-ADL scores
showed a decline at 52 weeks compared to control (Fig. 3b)
in both placebo (p < 0.001) and resveratrol (p < 0.001)
groups; however, the decline in placebo was twofold
greater than resveratrol at week 52 (Fig. 3c), suggest-
ing that resveratrol may slow progressive cognitive
and functional decline in mild to moderate AD sub-
jects. There is no statistically significant association
between the change in MMSE and change in each of
Table 2 Summary of statistical tests of null changes between baseline and 52 weeks and tests of null differences at baseline using
all detected molecules in plasma of patients treated with placebo (N = 19) or resveratrol (N = 19)
Analytes Between baseline and 52 weeks At baseline
Paired t test Unpaired t test Wilcoxon signed rank
test
Baseline: active vs placebo
Placebo Active Placebo Active Unpaired t test (unequal) Unpaired t test (equal) Wilcoxon signed rank test
MMP-9 0.1477 0.8332 0.7577 0.2412 0.6319 0.8751 0.8737 1.0000
MMP-3 0.3193 0.0062** 0.065 0.3575 0.0102* 0.6911 0.6882 0.9311
MMP-2 0.5783 0.1647 0.1671 0.7148 0.177 0.8828 0.8828 0.8509
MMP-10 0.4557 0.0243* 0.0106* 0.5417 0.0353 0.9415 0.9410 0.6807
MMP-12 0.457 0.9138 0.4917 0.4631 0.9306 0.3667 0.3787 0.3310
MMP-13 0.1897 0.3379 0.0489* 0.3575 0.421 0.0598 0.0722 0.0938
MMP-1 0.7483 0.9518 0.7139 0.4263 0.8129 0.1371 0.1264 0.1059
FGF-2 0.6374 0.9743 0.6426 0.7002 0.6701 0.6751 0.6774 0.5508
G-CSF 0.3334 0.4526 0.2682 0.4131 0.5703 0.2042 0.2422 0.4195
MDC 0.7177 0.8208 0.1778 0.7148 0.7605 0.0458 0.0566 0.0678
PDGF-AA 0.8196 0.5719 0.3956 0.583 0.5421 0.9883 0.9886 0.8957
PDGF-AB/BB 0.2176 0.889 0.998 0.3258 0.9246 0.6349 0.6261 0.7881
IL-8 0.2096 0.7207 0.0322* 0.5416 0.9794 0.9648 0.9648 0.6450
EGF 0.5238 0.5667 0.7799 0.4263 0.8564 0.8870 0.8815 0.7234
Eotaxin 0.5987 0.0518 0.0697 0.5016 0.0611 0.7968 0.8017 0.8212
GM-CSF 0.6863 0.4321 0.3562 0.8501 0.4648 0.5001 0.4856 0.6638
Fractalkine 0.8863 0.8397 0.8579 0.9032 0.9245 0.4541 0.4543 0.8641
IFNα2 0.8981 0.8459 0.9661 1 0.9622 0.8727 0.8729 0.6194
IFNy 0.8316 0.438 0.8992 0.7148 0.463 0.8357 0.8406 0.8745
GRO 0.3481 0.6638 0.8992 0.2958 0.9622 0.9496 0.9478 0.5825
IL-12P40 0.6103 0.0485* 0.6473 0.9102 0.0781 0.2033 0.1897 0.3816
IL-12P70 0.5558 0.0404* 0.8159 0.7344 0.0424* 0.6327 0.6141 0.7730
sCD40L 0.3657 0.793 0.9062 0.3258 0.9653 0.6623 0.6483 0.8802
IL-17A 0.3792 0.7593 0.1786 0.4752 0.8158 0.3152 0.2696 0.6923
IL-1RA 0.0462* 0.4993 0.6706 0.0137* 0.7615 0.0880 0.0802 0.0317
IL-2 0.8926 0.0311* 0.9868 1 0.0547 0.2103 0.2015 0.2712
IP-10 0.1619 0.0673 0.0975 0.1353 0.0742 0.3900 0.3918 0.8509
MCP-1 0.5574 0.0637 0.2533 0.7148 0.0523 0.8650 0.8650 0.9864
MIP-1a 0.3696 0.2241 0.588 0.3594 0.1289 0.0175 0.0247 0.0440
MIP-1b 0.3694 0.6581 0.5786 0.3652 0.8469 0.7722 0.7632 0.8401
RANTES 0.8545 0.0335* 0.2919 0.9515 0.0366* 0.9889 0.9889 0.9699
TNFα 0.0221* 0.2091 0.7741 0.0161* 0.463 0.4081 0.4298 0.5861
Indicated in bold typeface represents significant associations (at level 0.05) after the Benjamini–Hochberg correction
*p<0.05
**p<0.1
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Fig. 1 ELISA concentrations of a MMP9, b IL-4, c MDC, d FGF2, e Aβ42, and f Aβ40 in the CSF from patients treated with placebo (N = 19) or
resveratrol (N = 19) for 52 weeks. Mean ± SD, p values and statistical methods are listed in Table 1
Fig. 2 ELISA concentrations of a MMP10, b IL-1R4, c IL-12P40, d IL-12P70, e TNFα, and f RANTES in plasma from patients treated with placebo
(N = 19) or resveratrol (N = 19) for 52 weeks. Mean ± SD, p values and statistical methods are listed in Table 2
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CSF or plasma biomarker between baseline and 52 weeks
(Table 3).
Discussion
One of the most striking results of this study is the
significant decrease in the level of CSF MMP9 after
resveratrol treatment. MMP9 has recently emerged as
a major player in several brain pathologies, including
neurodegeneration and neuro-inflammation [5]. MMP9
regulates BBB permeability via release of cytokines and free
radicals as well as cleavage of vascular basal lamina and/or
tight junctions in the neurovascular unit in both MS and
AD [6–8]. The decrease in CSF MMP9 levels suggests that
resveratrol treatment may reduce CNS permeability and
limit the infiltration of leukocytes and other inflammatory
agents into the brain. MMP9-mediated breakdown of the
basal lamina and destruction of gap junctions in the neuro-
vascular unit result in increased CNS permeability and
inflammation in autoimmune encephalitis, hypoxic brain
injury, and other diseases [9, 10]. MMP9 knockout reduces
neuro-inflammation in experimental autoimmune en-
cephalomyelitis (EAE) [11], while CSF MMP9 is elevated
in patients with bacterial meningitis and BBB damage
[12]. Moreover, inhibition of MMP9 alleviates the neuro-
logical damage associated with human immunodeficiency
virus (HIV) infection [13], suggesting that MMP9 activa-
tion is a response to HIV infection. These data are also
supported by enhanced expression and activity of MMP9
in serum, CSF, and demyelinating lesions in MS [14], and
abundant evidence of increased MMP9 expression and
activity in ischemic stroke [15, 16]. Animal studies have
also revealed significant increases in MMP9 levels after
traumatic brain injury [17], but damage to the BBB and
behavioral deficits are significantly attenuated in MMP9
knockout animals [18, 19].
MMP9 is highly regulated both spatially and temporally
with many target substrates including growth factors, cell
surface receptors, and cell adhesion molecules. Low levels
of MMP9 messenger RNA (mRNA) and protein expression
are detected predominantly in neurons in the hippocam-
pus, cerebellum and cerebral cortex of normal brain [20],
but injury significantly increases the mRNA and protein
levels and activity of MMP9 [5, 21, 22], which may be de-
rived from brain cells or leukocyte invasion of the brain
due to BBB compromise. Intercellular adhesion molecule-5
(ICAM-5), which mediates the regulation of dendritic spine
elongation and maturation may be cleaved by MMP9 upon
activation of N-methyl-D-aspartate (NMDA) receptors
[23, 24], suggesting a role for MMP9 in synaptic func-
tion. Furthermore, MMP9 deletion increases the num-
ber of CA1 pyramidal neurons and decreases the length
and complexity of dendritic spines [25]. Immune system
dysfunction may develop with aging in parallel with up-
regulation of brain MMP9 [26–28]. However, a recent
study showed that CSF MMP9 was significantly lower in
AD subjects with decreased Aβ42 and Aβ40 and increased
total tau and p-tau levels compared to healthy controls
[29]. In the current study, the levels of CSF tau and p-tau
were not altered by treatment but the levels of CSF Aβ42
and Aβ40 were altered in parallel with a reduction of
MMP9. However, there was no difference in the level of
CSF MMP9 between placebo and resveratrol-treated
groups at baseline, and it is uncertain whether MMP9
in our study population with AD is different from
healthy controls. MMP9 activation is likely driven by
other MMPs [30], so we examined the level of MMPs
in plasma and CSF. Leukocyte penetration into brain
parenchyma in EAE models involves β-dystoglycan
cleavage that is only abolished in double MMP2 and
MMP9 knockout mice [31], suggesting the effects of
other MMPs on MMP9 function. MMP10 and MMP3
were slightly increased in the plasma but not CSF of
AD patients. MMP9 has overlapping substrates with
other MMPs that share similar structures [5], so cau-
tion must be used in the interpretation of specific
MMP9 targets. MMP9 also plays a role in post-natal
brain development during a critical period of synaptic
formation and maturation and axonal myelination [32].
Fig. 3 Histograms represent a MMSE scores and b ADCS-ADL and c changes in ADL in placebo versus resveratrol groups in patients treated with
placebo (N = 19) or resveratrol (N = 19) for 52 weeks. Mean ± SD, **p < 0.01, ***p < 0.001
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In the adult brain MMP9 and MMP3 may be involved
in neurogenesis and migratory response mechanisms
[33]. MMP9 is upregulated in delayed and acute phases
of post ischemic stroke models [34, 35].
MMP9 regulates the CNS immune response due to its
ability to activate inflammatory markers and its involve-
ment in BBB maintenance, leading to its regulation of
entry of leukocytes into the brain parenchyma [5]. MDC/
CCL22 is a small cytokine that belongs to the Cysteine-
Cysteine (CC) family and is involved in transport of
natural killer cells, chronically activated T lymphocytes
(Th2) [36], monocytes, and dendritic cells into injury sites
[37]. MDC is expressed in the CNS and is produced by
CNS-infiltrating leukocytes and intra-parenchymal micro-
glia in EAE models [38]. Activated microglia secrete MDC
that induces chemotaxis of Th2, but not Th1, cells sug-
gesting that MDC produced by microglia regulates neuro-
inflammation via recruitment of Th2 cells into the injury
site [38]. Leukocyte infiltration into CNS white matter
lesions, which contain CD4+ and CD8+ T cells and acti-
vated macrophages/microglia, is a hallmark of MS [39].
Taken together, these findings support the hypothesis that
the increase in CNS MDC with resveratrol may facilitate
the intracerebral homing of specific leukocytes involved in
brain injury in AD, providing a mechanism for responding
to amyloid-associated inflammation [40]. MDC is involved
in Th2-driven chronic inflammation [41], and this is
consistent with the increase of CNS levels of IL-4,
which mediates an adaptive immune response via Th2
cell induction [42, 43], leading to a long-term protect-
ive immune response. Our results are also consistent
with the function MMPs that play an integral role in
immune cell development, effector function, migration,
and ligand-receptor interactions [44]. T helper cells
(Th1 and Th2) secrete MMP9 [45], which plays a critical
role in the migration of T cells from the blood stream to
the brain and other tissues [46, 47]. Additionally, recent
advances in neuro-inflammation implicate abnormal
neurotrophic factor signaling, including fibroblast growth
factors (FGFs) in HIV-associated neurocognitive decline
(HAND) [48] and stroke [49]. The increase in CNS FGF
levels after resveratrol treatment suggests an effect on
growth factors, which may play a role in neuro-resilience
in aging and AD.
Neuro-inflammation may contribute to cognitive im-
pairment and play a significant role in AD progression.
Activation of specific microglia/macrophage may be
neuroprotective. Although resveratrol treatment did
not affect CSF tau, resveratrol significantly attenuated
the declines in CSF Aβ42 and Aβ40 levels (compared to
placebo) and attenuated cognitive and functional decline
(MMSE and ADCS-ADL) between the placebo and treated
groups. Resveratrol also reduced the plasma levels of
pro-inflammatory makers including IL-1R4, IL-12P40,
IL-12P70, TNF-α, and RANTES, independent of CSF
changes of the levels of these biomarkers.
Innate immune cells, including CNS resident microglia
and peripheral bone marrow-derived macrophages can
exhibit a dysfunctional or senescent profile characterized
by impaired phagocytosis as AD progresses, indicating
that modification of the microglia/macrophage activa-
tion state, instead of inhibiting their function, may hold
Table 3 Summary of statistical tests of associations between
changes in MMSE for 52 weeks and changes in each biomarker
for 52 among patients treated with placebo (N = 19) or resveratrol
(N = 19)
Association between changes in MMSE and changes in biomarkers
CSF p value Plasma p value
Aβ40 0.8367 MMP-9 0.1061
Aβ42 0.2180 MMP-3 0.1358
pTau 181 0.4521 MMP-2 0.4234
tTau 0.6607 MMP-10 0.6379
MMP-9 0.1061 MMP-12 0.9992
MMP-3 0.1358 MMP-13 0.5432
MMP-2 0.4234 MMP-1 0.9490
MMP-10 0.6379 FGF-2 0.5382
FGF-2 0.5382 G-CSF 0.3103
TGFα 0.1270 MDC 0.7157
G-CSF 0.3103 PDGF-AA 0.2266
MCP-3 0.8066 PDGF-AB/BB 0.8598
MDC 0.7157 IL-8 0.0705
PDGF-AA 0.2266 EGF 0.3491
IL-4 0.7163 Eotaxin 0.2782
PDGF-AB/BB 0.8598 GM-CSF 0.9380
IL-8 0.0705 Fractalkine 0.4894
Flt-3L 0.2061 IFNα2 0.9855
Fractalkine 0.4894 IFNy 0.3895
IFNα2 0.9855 GRO 0.2955
IL-15 0.8288 IL-12P40 0.7747
IL-7 0.8204 IL-12P70 0.8371
IP-10 0.2102 sCD40L 0.3075
MCP-1 0.2516 IL-17A 0.8985








Indicated in bold typeface represents significant associations (at level 0.05)
after the Benjamini–Hochberg correction
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therapeutic promise in AD [50–52]. Resveratrol may
facilitate activation of microglia/macrophages therefore
inducing a long-term adaptive immune response that
may be clinically beneficial in AD subjects. Major im-
pediments of current immunotherapy approaches to AD
include limited evidence of significant clinical benefits,
and the risk of excessive neuro-inflammation [53].
Conclusions
Resveratrol may maintain the integrity of the BBB via
reduction of MMP9 and induce adaptive immune re-
sponses that may promote brain resilience to amyloid
deposition. Resveratrol may slow cognitive decline in
AD via a coordinated peripheral and central immune
response that may also arrest neuronal death. In conclu-
sion, the exploratory findings of the current study encour-
age further validation of the hypothesis that resveratrol
may seal off a leaky BBB and contribute to cognitive and
functional improvement in a larger follow-up study with
AD patients.
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